Australian trial reveals new drug slows Alzheimer’s progression in over-75s by 30 per cent

详细摘要
An Australian-developed drug that targets stress hormones in the brain has emerged as a potential weapon against the condition that kills more Australians than any other disease.
A drug aimed at reducing Alzheimer’s symptoms in patients has shown promising results in older Australians, the biotech company behind the medicine has revealed.
Australian biotech company Actinogen released the results of their phase 2 trials of the drug Emestedastat, which works by blocking the production of the stress hormone cortisol in key areas of the brain, on Thursday.
Developed under the brand name Xanamem, the trial involved 247 patients in Australia and the US with mild to moderate disease, taking a daily pill over a 36-week course of treatment.
While it showed it slowed the progression of the disease by 30 per cent in those over the median age of 75 – representing half the trial group – it did not record a statistically significant benefit in the overall trial group.
According to Actinogen, most participants in the trial experienced few side effects during the 36 weeks.
Actinogen chief executive Steven Gourlay said a recent $10.8m research and development tax incentive rebate awarded by the federal government put them in a stronger cash position amid the trial.
“It encourages companies like us to do as much research in Australia as we can,” Dr Gourlay said.
“So it’s been good for Australian jobs, it’s been good for Australian science, and it’s been great for helping companies like us to do the work that we need to do to answer important questions like, ‘Does this drug that controls cortisol work in Alzheimer’s disease?’,” he said.
The next trial is expected to involve 700 patients and would begin in mid-2027, with the company hoping to get the drug to market in 2030.
文章开头,摘自PerthNow。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.perthnow.com.au)
